Neurofeedback and qEEG brain mapping marketing: ADHD, anxiety and autism claims

Neurofeedback and qEEG “brain mapping” clinics tend to market with big promises: “drug-free ADHD treatment,” “retrain your brain and end anxiety,” “see what is wrong in your brain,” “FDA-cleared neurofeedback,” “improves autism symptoms.” Some of those phrases point at real FDA records. Several of them stretch those records well past what they say.

This guide sets out what FDA’s device rules and clearances say about biofeedback, EEG neurofeedback and quantitative EEG, what NIH says about neurofeedback for ADHD, and how FTC rules apply to condition claims, brain map reports, testimonials and packages. We do not name any device, software, brand or company. For the evaluation side of ADHD and autism services, see our guide to ADHD and autism evaluation marketing. For another brain-based device service with its own FDA record, see our guide to TMS clinic marketing.

The short version

• Biofeedback is a regulated device type. 21 CFR 882.5050 covers devices that feed back a body signal, including brain alpha wave activity, so a patient can learn to control it. The listed uses are relaxation training and muscle reeducation.
• One EEG neurofeedback clearance names a condition, and it is PTSD. A software device cleared in March 2023 (K222101) is indicated for relaxation and stress reduction and as an adjunctive treatment of PTSD symptoms, under a healthcare professional’s direction. It is not an ADHD, anxiety disorder or autism clearance.
• No neurofeedback product code names ADHD or autism. The three product codes under 882.5050 cover biofeedback in general, stress and anxiety symptoms, and sleep assessment. The ADHD device types FDA has classified are an EEG assessment aid, a nerve stimulator and a digital therapy, none of them neurofeedback.
• A qEEG brain map is not a diagnosis. The only EEG device type for ADHD is an assessment aid that FDA says must not be used as a stand-alone diagnostic. Normative qEEG software is cleared for interpretation by a qualified user, and the newest clearance says it provides no diagnosis.
• NIH calls neurofeedback a newer treatment under study. NIMH lists medication and psychosocial interventions as standard ADHD treatments.

What FDA’s biofeedback rule covers

21 CFR 882.5050 defines a biofeedback device as an instrument that gives a visual or auditory signal tied to one or more of a patient’s physiological parameters, with brain alpha wave activity, muscle activity and skin temperature as examples, so that the patient can control those parameters voluntarily. EEG neurofeedback fits that definition. The device is Class II, and the rule exempts it from premarket notification only when it is a prescription, battery-powered device indicated for relaxation training and muscle reeducation.

openFDA’s classification data (last updated October 19, 2026) lists three product codes under that regulation:

• HCC, biofeedback device. The general code, with 172 510(k) records in openFDA.
• SEN, biofeedback for adjunctive treatment of symptoms associated with stress and anxiety. FDA’s definition is feedback on a physiological measurement as a relaxation treatment for the reduction of stress and anxiety. It has one 510(k), cleared April 24, 2025, for a breathing device, not an EEG device.
• LEL, sleep assessment device. Not a treatment code.

Two things follow for marketing. First, the wording FDA uses is “relaxation,” “stress reduction” and “adjunctive treatment of symptoms,” not “treats anxiety disorder” or “cures ADHD.” Second, a clinic’s own device may have no condition-specific clearance at all. Before you name a condition, look up your system’s 510(k) number and read the indications statement.

The EEG neurofeedback clearance for PTSD

The 510(k) record that names a condition for EEG neurofeedback is K222101, cleared March 17, 2023 under code HCC. Its indications statement describes a neurofeedback software device intended for relaxation and stress reduction through EEG biofeedback, indicated as an adjunctive treatment of symptoms associated with PTSD, to be used under the direction of a healthcare professional together with other drug or non-drug treatments.

The clinical study in the 510(k) summary is worth knowing before anyone quotes it. It was a single-arm, open-label, unblinded study of adults aged 22 to 65 with chronic PTSD, with 15 sessions over 8 weeks. Of 101 people screened, 79 were in the full analysis set and 66 in the efficacy set. At the 3-month follow-up, 66.67% of the efficacy set had at least a 6-point drop on the clinician PTSD scale. There was no control group, and 50.6% of participants had adverse events, mostly mild headache and fatigue.

So a PTSD-focused page can accurately say that FDA cleared an EEG neurofeedback software device as an add-on to other PTSD care, if that is the system you use. It cannot fairly say neurofeedback “treats PTSD on its own,” “is proven to work” or “replaces therapy or medication.” The clearance says adjunctive, and the study had no comparison group.

Cleared is not approved

A 510(k) clearance means FDA found a device substantially equivalent to one already on the market for the stated use. 21 CFR 807.97 says a clearance does not in any way denote official approval of a device, and that a representation creating that impression is misleading and constitutes misbranding. “FDA-approved neurofeedback” is the wrong phrase. “FDA-cleared” is accurate only for the specific system and the specific indications in its 510(k).

Under 21 USC 396, a clinician may use a legally marketed device as they judge best for a patient, but that section says it “shall not change any existing prohibition on the promotion of unapproved uses.” Training a patient with ADHD on a device cleared for relaxation is a clinical decision. A page that says “FDA-cleared neurofeedback for ADHD” turns that decision into a promotional claim FDA never reviewed. Our guide to medical device marketing claims covers clearance wording in more depth.

ADHD claims

NIMH’s ADHD page (last reviewed August 2026) says standard ADHD treatments include medication and psychosocial interventions such as cognitive behavioral therapy, parent training and school interventions. It lists neurofeedback with cognitive training, mindfulness and neuromodulation as newer treatments that researchers are studying and comparing. That is the federal health agency’s current framing, and ads should not contradict it.

FDA has classified three device types that name ADHD, according to openFDA, and none is neurofeedback:

• An EEG-based assessment aid (21 CFR 882.1440, code NCG). Created through the De Novo for a system that uses the EEG theta/beta ratio, with a clinician’s evaluation, to aid in the diagnosis of ADHD in patients 6 to 17. It is prescription only and “NOT to be used as a stand-alone” in evaluating or diagnosing ADHD.
• A transcutaneous nerve stimulator for ADHD (21 CFR 882.5898, code QGL). First classified through a De Novo granted April 19, 2019.
• Digital therapeutic software for ADHD (21 CFR 882.5803, code QFT). First classified through a De Novo granted June 15, 2020, as an adjunct to clinician-supervised treatment.

Phrases to drop or rework:

• “Drug-free ADHD treatment” and “get off medication.” These set neurofeedback against standard care that NIMH names, and they can push parents to stop treatment. If you say anything, say neurofeedback is offered alongside a child’s existing care, not instead of it.
• “FDA-cleared for ADHD.” We found no neurofeedback product code or clearance for ADHD in FDA’s classification data.
• “Permanent results” or “retrain the brain for life.” Durability is an outcome claim that needs competent and reliable scientific evidence.
• “Improves focus and grades in X sessions.” A specific outcome and time frame. Without evidence for your protocol, remove it.

Anxiety, depression and PTSD claims

Anxiety is where FDA’s wording is closest to what clinics want to say, which makes precision matter more. Code SEN covers biofeedback for adjunctive treatment of patient-reported symptoms associated with stress and anxiety, as a relaxation treatment. That is different from treating an anxiety disorder, and the one SEN clearance is not an EEG device.

• “Neurofeedback for stress and relaxation” stays close to the regulation’s own language.
• “Clinically proven to cure anxiety” or “end panic attacks” does not. It needs controlled evidence for the protocol you offer.
• “Treats depression” has no neurofeedback clearance behind it in FDA’s records. Depression-device claims are covered in our guide to TMS clinic marketing, which has its own FDA history.
• Any page that touches suicidal thoughts or crisis should give the 988 Suicide and Crisis Lifeline and 911, not a booking link.

Autism claims

NIMH describes autism as a neurological and developmental disorder that affects how people interact with others, communicate, learn and behave, with symptoms that generally appear in the first two years of life (page last reviewed December 2024). We found no FDA product code or clearance for neurofeedback or qEEG in autism, and NIMH’s page does not list neurofeedback as an autism treatment.

The FTC’s standard of competent and reliable scientific evidence applies to health claims made to parents. “Reduces autism symptoms,” “improves speech and eye contact” and “reverse autism” are disease claims with nothing in FDA’s records behind them. If your clinic sees autistic patients for something else, such as sleep or relaxation training, describe that service plainly and do not imply it treats autism. Our guide to ABA therapy marketing covers the evidence-based autism service side.

qEEG “brain mapping”: what the report can and cannot claim

qEEG brain maps are the front door for a lot of neurofeedback clinics, and the marketing often treats them as a diagnostic scan. FDA’s classifications say otherwise:

• The EEG itself (21 CFR 882.1400). A device that measures and records the brain’s electrical activity through electrodes on the head. Class II.
• Spectrum analysis (21 CFR 882.1420). A device that displays the frequency content or power spectral density of the EEG. Class I.
• Normalizing qEEG software (code OLU). FDA’s definition is post-hoc statistical analysis of EEG signals compared with a normative database, for interpretation by a qualified user. openFDA lists 13 510(k)s, from July 30, 1991 to June 12, 2026. The summary for the June 2026 clearance (K253015) says the software is for adults 18 to 70, is prescription only and “does not provide a diagnosis or clinical interpretation.”
• The ADHD assessment aid (21 CFR 882.1440). The regulation requires safeguards against stand-alone diagnostic use and labeling that warns against it. The decision summary for the one De Novo (K112711) limits that device to ages 6 to 17 and rules out patients with seizure history, anticonvulsant use, EEG abnormalities or metal in the head.

Wording that runs ahead of those records: “the brain map shows you have ADHD,” “see your anxiety on a scan,” “objective diagnosis in one hour,” “identify the root cause of your symptoms.” Wording that stays closer: “a qEEG recording compares your EEG patterns with a reference database. Your clinician reviews it alongside your history and other assessments. It is not a diagnosis on its own.” If a non-clinician staff member prepares maps, do not market them as a medical evaluation.

A qEEG appointment is also a health record. Our guide to tracking pixels on practice websites covers why booking pages for health assessments need care with ad tracking.

Outcome claims, session counts and the FTC

Section 5 of the FTC Act declares unfair or deceptive acts or practices unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of devices or services (15 USC 52). Under 15 USC 55(a)(1), whether an ad is misleading depends partly on what it fails to reveal. The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence, and the FTC reads an ad for its net impression.

• Session counts. “20 sessions” as a package is a price unit. “Results in 20 sessions” is an outcome promise. The PTSD clearance study used 15 sessions over 8 weeks for one indication in adults, which does not support a session count for children with ADHD.
• Percentages. “85% of our clients improve” needs a real, documented data set, a defined measure and a fair comparison. A satisfaction survey is not an outcome study.
• “Science-based” and “clinically proven.” These are establishment claims. The ad has to be backed by the level of evidence it implies.
• Omitted facts. If you mention the PTSD clearance, say it is adjunctive. If you show a brain map, say it is not a stand-alone diagnosis.

Testimonials, parent stories and before-and-after maps

Under 16 CFR 255.2(a), an advertiser needs substantiation for what a consumer endorsement conveys, as if it made the claim itself. Under 16 CFR 255.2(b), an endorsement about a key result is likely to be read as typical unless the ad clearly and conspicuously discloses the generally expected results. “My son’s ADHD is gone after neurofeedback” is an ADHD treatment claim made by the clinic, through the parent.

• Do not post stories that claim a cure or a stopped medication.
• Before-and-after brain maps imply a treatment effect. Show them only with what the change does and does not mean, and never as proof that a condition resolved.
• Get written authorization before using any patient’s or child’s story, map or image. See our guides to patient testimonials and before-and-after photos and patient photo consent for marketing.

Packages, prices and insurance wording

• Former prices. “Was $4,000, now $2,500” needs a former price you actually offered in good faith for a reasonably substantial period (16 CFR 233.1(a)).
• Refund promises. “Guaranteed results or your money back” still implies a result. Spell out the actual refund terms.
• Coverage. “Covered by insurance” is a factual claim. Say it only for plans you have confirmed, and say coverage depends on the plan and the reason for the service.

See our guide to advertising cash prices.

An example (made up)

This illustration is invented. A clinic posts: “FDA-approved neurofeedback! Our qEEG brain map pinpoints ADHD, anxiety and autism in one visit. Drug-free, permanent results in 20 sessions. 90% success rate. Package was $5,000, now $2,995.”

Fixes: “FDA-approved” comes off; clearance is not approval (21 CFR 807.97), and no neurofeedback clearance names ADHD, anxiety disorders or autism. “Pinpoints ADHD, anxiety and autism” comes off; the only EEG device type for ADHD is a stand-alone-prohibited assessment aid for ages 6 to 17, and qEEG normative software provides no diagnosis. “Drug-free” and “permanent” come off; NIMH lists medication among standard ADHD treatments and calls neurofeedback a newer treatment under study. The “90%” comes off unless the clinic has a documented outcome data set. The former price stays only if patients actually paid $5,000 for a reasonable period. A version that works: “Neurofeedback training for stress and relaxation, offered alongside your existing care. A qEEG recording helps your clinician plan sessions, and it is not a diagnosis on its own. Results vary. Book a consultation to talk through whether it fits.”

Checklist

• No “FDA-approved”; “FDA-cleared” only for your system and its 510(k) indications (21 CFR 807.97; 21 USC 396).
• Relaxation and stress wording, matching 21 CFR 882.5050 and code SEN, rather than disorder treatment claims.
• No ADHD, autism, anxiety-disorder or depression treatment claims without evidence and no implication that FDA reviewed them.
• PTSD mentions say adjunctive, under a professional’s direction, with other care (K222101).
• Brain maps described as a recording compared with a database, not a diagnosis (21 CFR 882.1440; code OLU; K253015).
• No “drug-free” or “get off medication” pitch (NIMH ADHD page).
• Outcome numbers, session counts, testimonials and maps backed and disclosed (15 USC 45, 52, 55; 16 CFR 255.2).
• Former prices, refunds and insurance wording real and clear (16 CFR 233.1).
• 988 and 911 on any page that touches crisis.

How we help

We build pages for behavioral health and neurology practices with claims checked against the sources above: website design, healthcare SEO for searches like “neurofeedback near me” and “qEEG brain map,” and lead generation campaigns that describe neurofeedback without approval, diagnosis or cure claims. We do not decide which treatment fits a patient, we do not give legal opinions, and we are not a law firm. Related guides: concussion clinic marketing and therapist private practice marketing.

Sources

• 21 CFR 882.5050: Biofeedback device
• 21 CFR 882.1400: Electroencephalograph
• 21 CFR 882.1420: Electroencephalogram (EEG) signal spectrum analyzer
• 21 CFR 882.1440: Neuropsychiatric interpretive electroencephalograph assessment aid
• 21 CFR 807.97: Misbranding by reference to premarket notification
• openFDA device classification data (last updated October 19, 2026)
• openFDA device 510(k) data (last updated October 19, 2026)
• FDA De Novo decision summary: EEG-based ADHD assessment aid (K112711)
• FDA 510(k) database: K222101 (March 17, 2023)
• FDA 510(k) database: K253015 (June 12, 2026)
• NIMH: Attention-Deficit/Hyperactivity Disorder (last reviewed August 2026)
• NIMH: Autism Spectrum Disorder (last reviewed December 2024)
• 21 USC 396: Practice of medicine
• 15 USC 45: Unfair methods of competition unlawful
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 16 CFR 233.1: Former price comparisons

More in Mental and behavioral health marketing